Table 2.
Selected RSV vaccines under clinical development
| Types of vaccine | Vaccine name | Description | Clinical status | Clinical trial number |
|---|---|---|---|---|
| Live attenuated vaccine | RSV MEDI ΔM2-2 | A M2-2 gene-deleted live attenuated vaccine | Phase 1 | NCT01459198 |
| RSV LID ΔM2-2 | A M2-2 gene-deleted live attenuated vaccine | Phase 1 | NCT02952339; NCT02601612; NCT02237209 | |
| LID/∆M2-2/1030s | An optimized M2-2 gene-deleted live attenuated vaccine | Phase 1 | NCT02794870 | |
| RSV ΔNS2 Δ1313 I1314L | An optimized NS2 gene-deleted live attenuated vaccine | Phase 1/2 | NCT03227029; NCT03422237 | |
| RSV 6120/∆NS2/1030s | An optimized NS2 gene-deleted live attenuated vaccine | Phase 1/2 | NCT03387137 | |
| RSV 6120/ΔNS1 | An optimized NS1 gene-deleted live attenuated vaccine | Phase 1 | NCT03596801 | |
| D46/ns2/N/∆M2-2-HindIII | An optimized M2-2 gene-deleted live attenuated vaccine | Phase 1 | NCT03099291; NCT03102034 | |
| Protein/subunit vaccine | VRC-RSVRGP084-00-VP | An F protein vaccine developed on the basis of the trimer pre-F protein DS-Cav1 | Phase 1 | NCT03049488 |
| GSK3844766A and GSK3888550A | An F protein vaccine developed on the basis of the F/pre-F protein | Phase 1/2 | NCT04126213; NCT04138056; NCT04090658 | |
| DepoVax (DPX)-RSV | An SH protein vaccine developed on the basis of lipid agent DepoVax | Phase 1 | NCT02472548 | |
| BARS13 | A G protein vaccine | Phase 1 | ACTRN12618000948291 | |
| Vector-based vaccine | Ad26.RSV.preF | Ad26 vector-encoding gene of the pre-F protein | Phase 2b | NCT03982199 |
| SeVRSV | SeV vector-encoding gene of the full-length F protein | Phase 1 | NCT03473002 | |
| GSK3389245A (ChAd155-RSV) | ChAd155 vector-encoding gene of the F, N and M2-1 proteins | Phase 1/2 | NCT03636906; NCT02927873 | |
| MVA-BN RSV | MVA-BN vector-encoding gene of the F, G, N and M2 proteins | Phase 2 | EUCTR2017-004582-27-BE | |
| mRNA-based vaccine | mRNA-1345 | Encoding a prefusion F glycoprotein | Phase 1 | NCT04528719 |
Ad26, adenovirus serotype 26; SeV, Sendai virus (also named mouse parainfluenza virus type 1); ChAd155, chimpanzee adenovirus-155; MVA-BN, modified Vaccinia Ankara from Bavarian Nordic. Sources: https://www.path.org/resources/rsv-and-mab-trial-tracker/?i=2682.